Affimed Therapeutics downgraded by H.C. Wainwright
$AFMD
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright downgraded Affimed Therapeutics from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2025 | Buy → Neutral | H.C. Wainwright | |
| 5/13/2025 | Outperform → Market Perform | Leerink Partners | |
| 12/12/2022 | $6.00 | Buy | H.C. Wainwright |
| 10/10/2022 | $9.00 → $2.00 | Buy → Hold | Stifel |
| 8/18/2022 | Overweight | Wells Fargo | |
| 3/31/2022 | $7.00 | Overweight | Piper Sandler |
| 2/23/2022 | $12.00 | Overweight | Cantor Fitzgerald |
| 10/21/2021 | $10.00 | Buy | Truist |